Thinking of joining a study?

Register your interest

Become a volunteer?

NCT06698939 | NOT YET RECRUITING | Healthy Volunteers

ORKA-001 in Healthy Volunteers
Sponsor:

Oruka Therapeutics, Inc.

Brief Summary:

This is a Phase 1, First-in-human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ORKA-001 in Healthy Participants.

Condition or disease

Healthy Volunteers

Intervention/treatment

ORKA-001

Placebo

Phase

PHASE1

Detailed Description:

This is a single center, phase 1, double-blind, placebo-controlled, randomized, first-in-human (FIH), single ascending dose study evaluating the safety, tolerability, and pharmacokinetics (PK) of ORKA-001 in healthy volunteers. The study will enroll approximately 24 healthy volunteers. The ORKA-001 dose will be administered by a subcutaneous injection.

Study Type : INTERVENTIONAL
Estimated Enrollment : 24 participants
Masking : DOUBLE
Primary Purpose : OTHER
Official Title : Phase 1, First-in-human, Double-Blind, Placebo-Controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics, of ORKA-001 in Healthy Participants
Actual Study Start Date : 2025-03
Estimated Primary Completion Date : 2026-06
Estimated Study Completion Date : 2026-06

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years to 65 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: 1
Criteria
Key Inclusion Criteria
  • 1. Healthy male or female participants
  • 2. 18 to 65 years (inclusive) with a body mass index (BMI) 18 to 32 kg/m2
  • 3. Willing and able to remain at the study site unit for the duration of the confinement period and return for the outpatient visit/s defined in the protocol
  • 4. Using a highly effective method of contraception from admission through the end of the study.
  • 5. Willing to abstain from regular, continuous alcohol use or tobacco use as per protocol
  • Key Exclusion Criteria
    • 1. Any clinically significant medical condition or finding that, in the Investigator's opinion, is likely to unfavorably alter the risk of study participation, confound study results, or interfere with the study conduct or compliance.
    • 2. Known history of illicit drug use or drug abuse or harmful alcohol use
    • 3. Known history of frequent tobacco or vaping use within 2 years prior to Screening
    • 4. History of severe allergic reactions or hypersensitivity
    • 5. Actively nursing or lactating
    • 6. Use of investigational drug therapy within 30 days prior to enrollment
    • 7. Unable to comply with study requirements or in the opinion of the Investigator should not participate in this study.
ORKA-001 in Healthy Volunteers

Location Details

NCT06698939

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

Not yet recruiting

New Zealand,

Oruka Therapeutics Investigative Site

Christchurch, New Zealand,